Introduction
============

Cancer is one of the main causes of death and is a challenge to healthcare systems around the world.[@b1-cmar-11-455] Epidemiological studies show that 14.1 million new cancer cases and 8.2 million cancer-related deaths occur annually worldwide, and these numbers are on the rise.[@b2-cmar-11-455],[@b3-cmar-11-455] Early diagnosis and prognosis prediction are helpful for choosing treatments for cancer patients, but traditional detection methods such as imaging techniques and biopsy have their limitations.[@b4-cmar-11-455],[@b5-cmar-11-455] Therefore, it is necessary to identify new biomarkers for early diagnosis and for predicting patients' prognosis to improve the efficacy of cancer treatment.

NIMA-related kinase 2 (NEK2), which is a member of the cell cycle-related kinase (CCRK) family of proteins, is a serine/threonine kinase located in the centrosome.[@b6-cmar-11-455] In recent years, determining the role(s) of NEK2 in tumor pathogenesis and progression has become a hotspot of research.[@b7-cmar-11-455],[@b8-cmar-11-455] Elevation in NEK2 level contributes to the formation of centrosomal abnormalities and monopolar spindles and promotes aneuploidy by disrupting the control of mitotic checkpoints.[@b9-cmar-11-455],[@b10-cmar-11-455] An increasing number of studies have reported that expression of NEK2 is increased in cancer and that up-regulation of NEK2 is associated with tumor progression and poor prognosis in various types of cancer, including breast cancer,[@b11-cmar-11-455],[@b12-cmar-11-455] colorectal cancer,[@b13-cmar-11-455],[@b14-cmar-11-455] cervical cancer,[@b15-cmar-11-455] and cholangiocarcinoma.[@b16-cmar-11-455] Notably, the number of studies on NEK2 is still small and the role, or roles, of NEK2 in cancer remains unclear. Overall, the reported results are inconclusive, and no consensus has been reached. Thus, we performed this meta-analysis to summarize the existing data and evaluate the prognostic value of NEK2 in cancer patients.

Methods
=======

Literature search strategy
--------------------------

A comprehensive literature search of online databases, including PubMed, Web of Science, Embase, and CNKI, was carried out to retrieve studies evaluating the association between NEK2 expression and clinical outcome in any type of tumor up to August 2017. The keywords for the literature search included: "NIMA-related kinase 2", "NEK2", "cancer", "tumor", "carcinoma", "neoplasm", "survival", or "prognosis". The references of eligible literature were also manually screened to further retrieve potentially eligible publications. Conflicts were solved through group discussion.

Inclusion and exclusion criteria
--------------------------------

To be eligible for inclusion, a study had to meet the following criteria: 1) the association of NEK2 level with the clinicopathological features or prognosis of cancer patients was described; 2) patients were categorized into two groups based on high and low expression levels of NEK2; and 3) the study provided the data for estimating the HRs and 95% CIs of survival outcomes. The exclusion criteria included: 1) studies that did not provide the correlation between NEK2 level and the clinicopathological features or prognosis of cancer patients; 2) duplicated publications; and 3) letters, reviews, case reports, and expert opinions.

Data extraction and quality assessment
--------------------------------------

Two investigators independently evaluated the included studies for the number of patients, name of the first author, year of publication, cancer type, TNM stage, follow-up period, outcome measures, methods for measuring NEK2 expression, HR and its 95% CI, and clinicopathological parameters from each study. The quality of included studies was assessed with the Newcastle--Ottawa Scale (NOS), which is composed of three domains: selection, comparability, and exposure. The NOS is a semi-quantitative scale, from which a score of 0--9 was assigned to each study. A total score of ≤3 was considered poor quality, 4--6 was considered moderate qualify, and 7--9 was deemed high quality.

Statistical methods
-------------------

The meta-analysis was performed with RevMan 5.3 software. The HR with corresponding 95% CI was used to estimate the strength of the relationship between NEK2 expression and prognosis of patients. Heterogeneity among studies was quantified using the chi-squared test and *I*^2^ statistics. A chi-squared test with *P*\<0.05 or *I*^2^\>50% indicated significant heterogeneity across the studies. If the heterogeneity was not significant, a fixed effects model was used to investigate the pooled HRs. A random effects model was used to summarize the statistical synthesis if among-study heterogeneity was substantial. Sensitivity analysis was also carried out to assess the stability of the results. Publication bias was estimated qualitatively using funnel plots with the standard error.

Results
=======

Study characteristics
---------------------

The initial literature search retrieved 322 relevant studies. According to the inclusion and exclusion criteria, 14 eligible studies with 3,280 enrolled patients were included in the present meta-analysis ([Figure 1](#f1-cmar-11-455){ref-type="fig"}). The characteristics of the included studies are summarized in [Table 1](#t1-cmar-11-455){ref-type="table"}. All studies were published in the past 4 years, suggesting that the value of NEK2 in predicting prognosis is a novel field of research. Regarding the type of cancer, four studies investigated hepatocellular carcinoma (HCC),[@b18-cmar-11-455],[@b20-cmar-11-455],[@b26-cmar-11-455],[@b28-cmar-11-455] three studies were focused on colorectal cancer,[@b23-cmar-11-455],[@b25-cmar-11-455],[@b29-cmar-11-455] two studies were focused on non-small cell lung cancer,[@b22-cmar-11-455],[@b24-cmar-11-455] and one each evaluated prostate cancer,[@b17-cmar-11-455] pancreatic ductal adenocarcinoma,[@b19-cmar-11-455] malignant glioma,[@b21-cmar-11-455] lung cancer,[@b27-cmar-11-455] multiple myeloma,[@b30-cmar-11-455] and breast cancer.[@b31-cmar-11-455] The maximum and minimum sample sizes of the included studies were 594 and 50, respectively. The followup time ranged from 40 to 240 months. All included studies were carried out in four countries (PR China, Japan, the UK, and the USA) and published prior to August 2017. The NOS method was applied to evaluate the quality of each study, and the mean score of the included studies was 8.6 (range 6--9).

Association between NEK2 and overall survival (OS)
--------------------------------------------------

Fourteen included studies assessed the HRs for poor OS. As shown in [Figure 2](#f2-cmar-11-455){ref-type="fig"}, no obvious heterogeneity among these studies was found (*I*^2=46%^, *P*=0.03). Thus, a fixed effects model was employed to evaluate the pooled association between NEK2 expression and OS of different types of malignancies. The HR of the high NEK2 level group vs the low NEK2 expression group was 1.72 (95% CI: 1.49--2.00, *P*\<0.00001), suggesting that up-regulated NEK2 expression was correlated with inferior OS in cancer patients ([Figure 2](#f2-cmar-11-455){ref-type="fig"}).

Subsequent stratified analyses were performed according to cancer type, sample size, follow-up period, HR estimation method, and country ([Figures 3](#f3-cmar-11-455){ref-type="fig"} and [4](#f4-cmar-11-455){ref-type="fig"} and [Table 2](#t2-cmar-11-455){ref-type="table"}). Increased NEK2 expression was associated with poor OS in patients with HCC (HR=1.62, 95% CI: 1.25--2.10, *P*=0.0002) or lung cancer (HR=2.18, 95% CI: 1.40--3.38, *P*=0.0005) ([Figure 3](#f3-cmar-11-455){ref-type="fig"}). In the analysis stratified by sample size, NEK2 expression was found to be significantly correlated with patient survival in studies with a sample size \<300 (HR=1.88, 95% CI: 1.43--2.46, *P*\<0.00001) or more than 300 (HR=1.59, 95% CI: 1.20--2.10, *P*=0.001) ([Figure 4A](#f4-cmar-11-455){ref-type="fig"}). There was a significant correlation between NEK2 expression level and patient survival in studies with follow-up time ≤100 months (HR=1.68, 95% CI: 1.09--2.59, *P*=0.02) or \>100 months (HR=1.95, 95% CI: 1.56--2.44, *P*\<0.00001) ([Figure 4B](#f4-cmar-11-455){ref-type="fig"}). Regarding the location of the study, the stratified analysis revealed a significant association between NEK2 level and OS in both Asian countries (HR=1.86, 95% CI: 1.45--2.38, *P*\<0.0001) and other countries (HR=1.55, 95% CI: 1.08--2.23, *P*=0.02) ([Figure 4C](#f4-cmar-11-455){ref-type="fig"}). In addition, the association was significant in studies with both direct (HR=2.01, 95% CI: 1.18--3.43, *P*=0.01) and indirect (HR=1.75, 95% CI: 1.37--2.23, *P*\<0.00001) HR estimation methods ([Figure 4D](#f4-cmar-11-455){ref-type="fig"}). Altogether, the subgroup analyses indicated that sample size, follow-up period, country, and HR estimation method did not have any significant influence on the correlation between NEK2 level and patient OS, suggesting that the association is stable and therefore highlighting the value of NEK2 as a prognostic biomarker for cancer patients.

Association between NEK2 and disease-free survival (DFS)
--------------------------------------------------------

As shown in [Figure 5](#f5-cmar-11-455){ref-type="fig"}, two studies with 697 patients investigated the role of NEK2 expression in DFS. However, the pooled analysis failed to show a significant correlation between NEK2 level and DFS of patients (HR=1.13, 95% CI: 0.29--4.38, *P*=0.85) ([Figure 5](#f5-cmar-11-455){ref-type="fig"}).

Correlation between NEK2 expression and clinicopathological parameters
----------------------------------------------------------------------

To examine whether the NEK2 level had an association with the clinicopathological parameters of patients, we pooled the clinicopathological data to conduct a meta-analysis. As shown in [Table 3](#t3-cmar-11-455){ref-type="table"}, increased NEK2 expression was negatively associated with age (OR=0.45, 95% CI: 0.11--1.84, *P\<*0.00001), but positively correlated with male gender (OR=3.02, 95% CI: 1.30--7.02, *P=*0.01), better tumor differentiation (OR=4.23, 95% CI: 1.30--13.77, *P\<*0.00001), and lower tumor nodule number (OR=5.88, 95% CI: 2.19--5.80, *P=*0.0004). However, NEK2 expression was not correlated with other clinicopathological features, including disease stage and tumor size ([Table 3](#t3-cmar-11-455){ref-type="table"}).

Sensitivity analysis
--------------------

A sensitivity analysis was then performed by removing each study in turn from the pooled analysis for the association between NEK2 level and OS. This analysis enabled us to examine the impact of the removed study on the overall HRs. The results revealed that removing any of the included studies had no significant influence on the final results, which suggested the robustness of the association ([Table 4](#t4-cmar-11-455){ref-type="table"}).

Publication bias
----------------

No significant publication bias was discovered in the included studies from the funnel plots ([Figure 6](#f6-cmar-11-455){ref-type="fig"}).

Discussion
==========

NEK2 belongs to the CCRK family of cell cycle-regulating proteins and it is a serine/threonine kinase located in the centrosome.[@b32-cmar-11-455]--[@b34-cmar-11-455] Previous studies have demonstrated that elevation in NEK2 contributes to the regulation of centrosome separation and spindle formation, and to ensuring that the chromosome structure is more stable and complete.[@b35-cmar-11-455],[@b36-cmar-11-455] In cancer-related studies, NEK2 was found to be up-regulated in various types of cancer tissues and cell lines, suggesting the involvement of NEK2 in tumorigenesis. NEK2 has also been shown to be involved in abnormal cell differentiation, tumor proliferation, drug resistance, and poor prognosis in several kinds of tumors.[@b37-cmar-11-455]--[@b39-cmar-11-455]

A lot of effort has been made to understand the functional role of NEK2 in cancer. Zhang et al found that NEK2 significantly enhanced the invasive ability of HCC cells, and epithelial--mesenchymal transition played a pivotal role in the NEK2-mediated promotion of HCC cell invasion.[@b28-cmar-11-455] Zhang et al demonstrated that NEK2 may regulate proliferation, apoptosis, and other biological behaviors of HepG2 cells via the mitogen-activated protein kinase signaling pathway.[@b40-cmar-11-455] Tsunoda et al showed that interfering with or silencing NEK2 expression could inhibit the invasive capacity of breast cancer cells.[@b41-cmar-11-455] Two groups reported that elevation in NEK2 contributed to the activation of the PI3K/AKT signaling pathway, a potent and critical oncogenic pathway for a variety of malignancies.[@b41-cmar-11-455],[@b42-cmar-11-455] Li et al reported that overexpression of NEK2 resulted in high expression of phospho-AKT and matrix metalloproteinase-2 proteins in HCC, which are key factors in HCC invasion and metastasis.[@b43-cmar-11-455] These results suggest that targeting NEK2 may be beneficial in the treatment of human cancers. However, the role of NEK2 in other non-studied types of cancer needs to be further investigated to fully understand the functions of NEK2 in cancer.

This meta-analysis is the first systematic review to comprehensively investigate the relationship between NEK2 expression and the OS of patients with different types of cancers. Survival data of 3,280 patients from 15 included studies were systematically analyzed. The pooled HRs suggested the value of NEK2 in predicting the OS in cancer patients. Regarding tumors originating from different tissues, high NEK2 expression was relevant to poor OS in HCC and lung cancer. Further subgroup analyses for sample size, follow-up time, HR estimation method, and country showed that the significance of NEK2 in OS was not affected by these factors. The meta-analysis for the association between increased NEK2 expression and clinicopathological parameters was also analyzed in this study. Our results showed that increased NEK2 expression was significantly associated with younger age, male gender, better tumor differentiation, and solitary tumor nodule. Overall, this study highlighted the potential of NEK2 as a prognostic biomarker for cancer patients.

However, this meta-analysis had some deficiencies and limitations. First, the total sample size was relatively small, and most of the patients included in the meta-analysis were from PR China, raising concerns when applying the results of this study to different ethnicities and regions. Therefore, more large-scale studies are warranted to further verify the prognostic value of NEK2 in different ethnicities and regions. Second, some included studies did not offer HRs directly, and we calculated the HRs using the Kaplan--Meier curves from these studies. This may compromise the validity of the conclusions. Third, publication bias may exist, as studies with small sample size or negative results are less likely to be reported, despite the fact that no significant publication bias was observed for the included studies upon sensitivity and funnel plot analyses. Therefore, larger, multicenter, and higher-quality studies with unified criteria for determining NEK2 expression are necessary to validate the conclusions of this study.

Conclusion
==========

In summary, our meta-analysis has demonstrated that high NEK2 levels in different types of solid tumors are significantly associated with poor prognosis. Accordingly, NEK2 has potential value as a prognostic biomarker for tumors. Nevertheless, this conclusion needs to be confirmed by larger-scale prospective studies in the future.
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###### 

Forest plot of the subgroup analyses evaluating HRs of NEK2 for overall survival by the factors of (**A**) sample size, (**B**) follow-up months, (**C**) region, and (**D**) HR estimation method.

**Abbreviations:** CC, colon cancer; HCC, hepatocellular carcinoma; LC, lung cancer; NEK2, NIMA-related kinase 2.
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###### 

Characteristics of the included studies

  Study (first author)                    Year   Country    Cancer type   No. of cases   Gender (M/F)   Follow-up (months)   Detection method   Outcome measurements   HR (95% CI)                                 NOS
  --------------------------------------- ------ ---------- ------------- -------------- -------------- -------------------- ------------------ ---------------------- ------------------------------------------- -----
  Zeng et al[@b17-cmar-11-455]            2015   PR China   PCa           180            NR/NR          140                  qRT-PCR            OS                     1.76 (0.85--3.64)                           7
  Fu et al[@b18-cmar-11-455]              2017   PR China   HCC           310            252/59         40                   IHC                OS                     1.44 (0.96--2.17)                           8
  Ning et al[@b19-cmar-11-455]            2014   PR China   PDA           136            72/64          100                  qRT-PCR            OS                     0.84 (0.56--1.38)                           8
  Li et al[@b20-cmar-11-455]              2017   PR China   HCC           63             52/11          116                  qRT-PCR            OS                     1.15 (0.39--3.35)                           8
  Liu et al[@b21-cmar-11-455]             2017   PR China   MG            105            47/52          200                  IHC                OS                     4.177 (1.97--8.82)                          9
  Zhong et al[@b22-cmar-11-455]           2014   PR China   NSCLC         270            192/78         60                   IHC                OS                     3.810 (2.06--7.036)                         8
  Takahashi et al[@b23-cmar-11-455]       2014   Japan      CRC           180            104/76         180                  qRT-PCR            OS                     1.76 (0.87--3.59)                           7
  Zhong et al[@b24-cmar-11-455]           2014   PR China   NSCLC         270            192/78         10                   IHC                OS                     1.85 (1.20--2.83)                           8
  Lu et al[@b25-cmar-11-455]              2015   PR China   CC            60             32/28          100                  IHC                OS                     3.04 (1.12--8.29)                           7
  Wubetu et al[@b26-cmar-11-455]          2016   Japan      HCC           50             16/34          180                  qRT-PCR            OS                     2.76 (1.12--8.29)                           8
  Shi et al[@b27-cmar-11-455]             2017   PR China   LC            349            159/190        240                  qRT-PCR            OS/DFS                 1.749 (1.140--2.681)/1.738 (1.161--2.601)   9
  Zhang et al[@b28-cmar-11-455]           2018   PR China   HCC           259            230/29         100                  qRT-PCR            OS                     1.72 (1.18--2.53)                           8
  Neal et al[@b29-cmar-11-455]            2014   UK         CC            103            57/46          NR                   IHC                OS/DFS                 1.654 (0.926--2.956)/2.393 (1.096--5.227)   8
  Gu et al[@b30-cmar-11-455]              2017   USA        MM            351            NR/NR          80                   qRT-PCR            OS                     1.80 (0.95--3.42)                           6
  Marina and Saavedra[@b31-cmar-11-455]   2014   USA        BC            594            NR/NR          133                  qRT-PCR            DFS                    0.6 (0.5--0.9)                              6

**Abbreviations:** BC, breast cancer; CC, colon cancer; CRC, colorectal cancer; DFS, disease-free survival; F, female; HCC, hepatocellular carcinoma; IHC, immunohistochemistry; LC, lung cancer; M, male; MG, malignant glioma; MM, multiple myeloma; NOS, Newcastle-Ottawa Scale; NR, not reported; NSCLC, non-small cell lung cancer; OS, overall survival; PDA, pancreatic ductal adenocarcinoma; PCa, prostate cancer.

###### 

Subgroup analysis of the pooled HRs for OS

  Categories             Studies (n)   No. of patients   Fixed effects model   Heterogeneity        
  ---------------------- ------------- ----------------- --------------------- --------------- ---- --------
                                                                                                    
  OS                     14            2,335             1.72 (1.49--2.00)     \<0.00001       46   0.03
  DFS                    2             697               1.13 (0.29--4.38)     \<0.00001       91   0.0007
  Cancer type                                                                                       
   HCC                   4             682               1.62 (1.25--2.10)     0.02            1    0.37
   CC                    2             163               1.82 (0.92--3.59)     0.08            44   0.18
   LC                    3             889               2.18 (1.40--3.38)     0.0005          58   0.09
  Sample size                                                                                       
   ≤300                  11            1,325             1.88 (1.43--2.46)     \<0.00001       57   0.010
   \>300                 3             1,010             1.59 (1.20--2.10)     0.001           0    0.78
  Follow-up                                                                                         
   ≤100 months           5             1,342             1.68 (1.09--2.59)     0.02            73   0.005
   \>100 months          8             1,077             1.95 (1.56--2.44)     \<0.00001       1    0.42
  HR estimation method                                                                              
   Indirect              11            2,129             1.75 (1.37--2.23)     \<0.00001       45   0.05
   Direct                3             557               2.01 (1.18--3.42)     0.01            66   0.05
  Country                                                                                           
   Asian                 12            2,232             1.86 (1.45--2.38)     \<0.0001        53   0.02
   Other                 2             451               1.55 (1.08--2.23)     0.02            0    0.57

**Abbreviations:** CC, colon cancer; DFS, disease-free survival; HCC, hepatocellular carcinoma; LC, lung cancer; OS, overall survival.

###### 

Association between NEK2 expression and clinicopathological features

  Clinicopathological parameters                  Studies (n)   Patients (n)   OR (95% CI)          *P*-value   Heterogeneity   
  ----------------------------------------------- ------------- -------------- -------------------- ----------- --------------- -----------
                                                                                                                                
  Age (≥65 vs \<65 years)                         3             403            0.45 (0.11--1.84)    \<0.00001   96              0.27
  Gender (male vs female)                         12            2,150          3.02 (1.30--7.02)    0.01        97              \<0.00001
  Clinical stage (I--II vs III--IV)               6             1,086          2.50 (0.78--8.03)    0.13        97              \<0.00001
  Tumor differentiation (well/moderate vs poor)   5             625            4.23 (1.30--13.77)   \<0.00001   95              \<0.00001
  Tumor nodule number (solitary vs multiple)      4             682            5.88 (2.19--5.80)    0.0004      93              \<0.00001
  Tumor size (≥5 vs \<5 cm)                       3             602            1.07 (0.16--7.31)    0.95        98              \<0.00001
  Venous invasion (present vs absent)             3             667            6.55 (0.86--49.59)   0.07        98              \<0.00001

**Abbreviation:** NEK2, NIMA-related kinase 2.

###### 

Sensitivity analysis

  Study (first author)                HR (95% CI)         *P*-value of heterogeneity   *I*^2^
  ----------------------------------- ------------------- ---------------------------- --------
                                                                                       
  Neal et al[@b29-cmar-11-455]        1.76 (1.51--2.06)   \<0.00001                    49
  Li et al[@b20-cmar-11-455]          1.74 (1.50--2.01)   \<0.00001                    49
  Wubetu et al[@b26-cmar-11-455]      1.70 (1.47--1.97)   \<0.00001                    48
  Liu et al[@b21-cmar-11-455]         1.66 (1.43--1.93)   \<0.00001                    35
  Lu et al[@b25-cmar-11-455]          1.70 (1.47--1.97)   \<0.00001                    48
  Fu et al[@b18-cmar-11-455]          1.77 (1.51--2.07)   \<0.00001                    48
  Zhong et al[@b22-cmar-11-455]       1.71 (1.46--2.00)   \<0.00001                    50
  Zhong et al[@b24-cmar-11-455]       1.64 (1.41--1.91)   \<0.00001                    31
  Zeng et al[@b17-cmar-11-455]        1.72 (1.48--2.00)   \<0.00001                    50
  Zhang et al[@b28-cmar-11-455]       1.72 (1.47--2.02)   \<0.00001                    50
  Shi et al[@b27-cmar-11-455]         1.72 (1.48--2.01)   \<0.00001                    50
  Takahashi et al[@b23-cmar-11-455]   1.72 (1.48--2.00)   \<0.00001                    50
  Ning et al[@b19-cmar-11-455]        1.85 (1.58--2.15)   \<0.00001                    22
  Gu et al[@b30-cmar-11-455]          1.72 (1.48--2.00)   \<0.00001                    50

[^1]: These authors contributed equally to this work
